ASCO® 2025 Highlights: Presenter Vignette – Aslaug Helland
Aslaug Helland
MD, PhD
Oslo Comprehensive Cancer Center
8011
ctDNA-based MRD detection in unresectable NSCLC undergoing curatively intended chemoradiotherapy and durvalumab.
Interested in learning more about these abstracts and other trials presented at ASCO® 2025? Be sure to register for one of our licensed Best of ASCO® events in a city near you.
This program has been made possible through unrestricted support from Boehringer Ingelheim, Eli Lilly and Ipsen
